Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
07 05 2021
Historique:
received: 04 08 2020
revised: 07 10 2020
accepted: 27 10 2020
pubmed: 16 4 2021
medline: 25 9 2021
entrez: 15 4 2021
Statut: ppublish

Résumé

Isolated REM sleep behaviour disorder (RBD) is an early-stage α-synucleinopathy in most, if not all, affected subjects. Detection of pathological α-synuclein in peripheral tissues of patients with isolated RBD may identify those progressing to Parkinson's disease, dementia with Lewy bodies or multiple system atrophy, with the ultimate goal of testing preventive therapies. Real-time quaking-induced conversion (RT-QuIC) provided evidence of α-synuclein seeding activity in CSF and olfactory mucosa of patients with α-synucleinopathies. The aim of this study was to explore RT-QuIC detection of α-synuclein aggregates in olfactory mucosa of a large cohort of subjects with isolated RBD compared to patients with Parkinson's disease and control subjects. This cross-sectional case-control study was performed at the Medical University of Innsbruck, Austria, the Hospital Clinic de Barcelona, Spain, and the University of Verona, Italy. Olfactory mucosa samples obtained by nasal swab in 63 patients with isolated RBD, 41 matched Parkinson's disease patients and 59 matched control subjects were analysed by α-synuclein RT-QuIC in a blinded fashion at the University of Verona, Italy. Median age of patients with isolated RBD was 70 years, 85.7% were male. All participants were tested for smell, autonomic, cognitive and motor functions. Olfactory mucosa was α-synuclein RT-QuIC positive in 44.4% isolated RBD patients, 46.3% Parkinson's disease patients and 10.2% control subjects. While the sensitivity for isolated RBD plus Parkinson's disease versus controls was 45.2%, specificity was high (89.8%). Among isolated RBD patients with positive α-synuclein RT-QuIC, 78.6% had olfactory dysfunction compared to 21.4% with negative α-synuclein RT-QuIC (P < 0.001). The extent of olfactory dysfunction was more severe in isolated RBD patients positive than negative for olfactory mucosa a-synuclein RT-QuIC (P < 0.001). We provide evidence that the α-synuclein RT-QuIC assay enables the molecular detection of neuronal α-synuclein aggregates in olfactory mucosa of patients with isolated RBD and Parkinson's disease. Although the overall sensitivity was moderate in this study, nasal swabbing is attractive as a simple, non-invasive test and might be useful as part of a screening battery to identify subjects in the prodromal stages of α-synucleinopathies. Further studies are needed to enhance sensitivity, and better understand the temporal dynamics of α-synuclein seeding in the olfactory mucosa and spreading to other brain areas during the progression from isolated RBD to overt α-synucleinopathy, as well the impact of timing, disease subgroups and sampling technique on the overall sensitivity.

Identifiants

pubmed: 33855335
pii: 6225983
doi: 10.1093/brain/awab005
doi:

Substances chimiques

Biomarkers 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1118-1126

Informations de copyright

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Ambra Stefani (A)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Alex Iranzo (A)

Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.

Evi Holzknecht (E)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Daniela Perra (D)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

Matilde Bongianni (M)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

Carles Gaig (C)

Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.

Beatrice Heim (B)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Monica Serradell (M)

Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.

Luca Sacchetto (L)

Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy.

Alicia Garrido (A)

Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.

Stefano Capaldi (S)

Biocrystallography Laboratory, Department of Biotechnology, University of Verona, Verona, Italy.

Almudena Sánchez-Gómez (A)

Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.

Maria Paola Cecchini (MP)

Department of Neurosciences, Biomedicine and Movement Sciences, Anatomy and Histology Section, University of Verona, Italy.

Sara Mariotto (S)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

Sergio Ferrari (S)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

Michele Fiorini (M)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

Joachim Schmutzhard (J)

Department of Otorhinolaryngology-Head and Neck Surgery, Medical University Innsbruck, Innsbruck, Austria.

Pietro Cocchiara (P)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

Isabel Vilaseca (I)

Department of Otorhinolaryngology, Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, CIBER-RES, Barcelona, Spain.

Lorenzo Brozzetti (L)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

Salvatore Monaco (S)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

M Jose Marti (M)

Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.

Klaus Seppi (K)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Eduardo Tolosa (E)

Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.

Joan Santamaria (J)

Neurology Service, Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain.

Birgit Högl (B)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Werner Poewe (W)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Gianluigi Zanusso (G)

Department of Neurosciences, Biomedicine and Movement Sciences University of Verona, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH